Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Issue 8 (28th April 2020)

• Record Type: Journal Article
• Authors: Jacob, Joseph; Aksman, Leon; Mogulkoc, Nesrin; Procter, Alex J; Gholipour, Bahareh; Cross, Gary; Barnett, Joseph; Brereton, Christopher J; Jones, Mark G; van Moorsel, Coline H; van Es, Wouter; van Beek, Frouke; Veltkamp, Marcel; Desai, Sujal R; Judge, Eoin; Burd, Teresa; Kokosi, Maria; Savas, Recep; Bayraktaroglu, Selen; Altmann, Andre; Wells, Athol U
• Is Part Of: Thorax. Volume 75:Issue 8(2020)
• Page Start: 648
• Page End: 654
• Publication Date: 2020-04-28
• Subjects: idiopathic pulmonary fibrosis -- bronchiectasis -- imaging/CT; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2019-213865
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Aims: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise. Methods: In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines. Results: On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent. Conclusions: Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines.